Fig. 2From: Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 studyMaximum change in a spleen volume and b palpable spleen length from baseline to week 24. Includes patients from the intent-to-treat population (n = 40). Each bar represents an individual patientBack to article page